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Abstract: Cytomegalovirus (CMV) retinitis is the most common cause of vision loss in 
patients with acquired immunodeficiency syndrome (AIDS). CMV retinitis afflicted 25% to 
42% of AIDS patients in the pre-highly active antiretroviral therapy (HAART) era, with most 
vision loss due to macula-involving retinitis or retinal detachment. The introduction of HAART 
significantly decreased the incidence and severity of CMV retinitis. Optimal treatment of 
CMV retinitis requires a thorough evaluation of the patient’s immune status and an accurate 
classification of the retinal lesions. When retinitis is diagnosed, HAART therapy should 
be started or improved, and anti-CMV therapy with oral valganciclovir, intravenous gan-
ciclovir, foscarnet, or cidofovir should be administered. Selected patients, especially those 
with zone 1 retinitis, may receive intravitreal drug injections or surgical implantation of a 
sustained-release ganciclovir reservoir. Effective anti-CMV therapy coupled with HAART 
significantly decreases the incidence of vision loss and improves patient survival. Immune 
recovery uveitis and retinal detachments are important causes of moderate to severe loss of 
vision. Compared with the early years of the AIDS epidemic, the treatment emphasis in the 
  post-HAART era has changed from short-term control of retinitis to long-term preservation of 
vision. Developing countries face shortages of health care professionals and inadequate supplies 
of anti-CMV and anti-HIV medications. Intravitreal ganciclovir injections may be the most cost 
effective strategy to treat CMV retinitis in these areas.
Keywords: cytomegalovirus, AIDS, retinitis, immune recovery uveitis, retinal detachment, 
treatment
Introduction
Cytomegalovirus (CMV), a ubiquitous organism, is the largest of the herpes 
viruses.1 The prevalence of individuals with evidence of prior CMV infection 
varies by age, geographic region, and sexual history. Nearly 60% of individuals 
over the age of six years and more than 80% of those older than 80 years exhibit 
seropositivity.2 In men infected with human immunodeficiency virus-1 (HIV) and 
having a history of homosexual behavior, the prevalence of CMV seropositivity 
exceeds 90%.3
Healthy individuals infected with CMV frequently remain asymptomatic, although 
some develop an influenza-like syndrome characterized by fever, chills, malaise, 
myalgias, and arthralgias. People with normal immune systems rarely develop 
long-term sequelae. Similar to other herpes viruses, CMV then enters a latent state, 
continually suppressed by cell-mediated immunity. CMV remains latent unless the 
patient suffers from a significant local (regional corticosteroid therapy) or systemic Clinical Ophthalmology 2010:4 286
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  immunodeficiency, acquired immunodeficiency syndrome 
(AIDS), pharmacologic immunosuppression to prevent 
allograft organ transplant rejection, local and systemic 
corticosteroid therapy, or an autoimmune condition such as 
Wegener’s granulomatosis. Recurrent CMV infections may 
cause colitis, encephalitis, or retinitis (which account for 
75% to 85% of CMV end-organ disease).4
The AIDS era began in 1981 when a group of five 
homosexual men developed unusual opportunistic infections 
(pneumocystis pneumonia, candidiasis, and CMV infections) 
due to severe immunodeficiency.5,6 The ocular abnormalities 
in these patients included a non-infectious occlusive retinal 
microvasculopathy (Figure 1), and progressive, necrotizing 
retinitis (Figure 2).7
During the first 14 years of the AIDS era, retinal 
  abnormalities were identified as the most significant ocular 
findings and the major cause of blindness in affected patients. 
Between 25% and 42% of AIDS patients developed CMV 
retinitis, the most common reason for severe vision loss.8–10 
Retinitis occurred in advanced AIDS patients with CD4+ 
T-lymphocyte counts of 50 cells/µL.11,12 Among patients 
with CD4+ T-lymphocyte counts 50 cells/µL the rate of 
CMV infection rate was 0.2 cases/person-year (PY).12
The introduction of highly active antiretroviral therapy 
(HAART) in 1996, originally defined as two nucleoside 
reverse transcriptase inhibitors (NRTIs) combined with 
a protease inhibitor (PI), and in 2004 expanded by the 
DHHS/Kaiser panel to include a PI, a non-nucleoside 
reverse transcriptase inhibitor, one of the NRTIs (abacavir or 
  tenofovir), an integrase inhibitor (eg, raltegravir), or an entry 
inhibitor (eg, maraviroc or enfuvirtide),13 became a watershed 
event in the treatment of HIV-infected patients. HAART 
decreased the mortality rate among HIV-infected patients, 
and significantly decreased the incidence and altered the 
natural history of many opportunistic infections, particularly 
CMV retinitis. Although most large centers have observed an 
80% decrease in the incidence of CMV retinitis, it remains 
the most common reason for vision loss in AIDS patients.14 
The incidence of CMV retinitis in the post-HAART era is 
estimated to be at most 5.6 cases/100 PY.15
Despite the changes in incidence and severity of retinitis 
caused by HAART, the ophthalmoscopic appearance of 
CMV retinitis does not appear to have changed. The Longi-
tudinal Study of the Ocular Complications of AIDS showed 
that the ocular findings in patients with newly diagnosed 
CMV retinitis in the post-HAART era resembled those prior 
to the introduction of HAART.16 However, differences in 
disease location, severity, and patient immune status have 
been reported.
On average, newly diagnosed CMV retinitis patients have 
CD4+ T-lymphocyte counts less than 50 cells/µL, but these 
values cover a broader range than in the pre-HAART era. 
Figure 1 Numerous cotton wool spots typical of Hiv retinopathy.Clinical Ophthalmology 2010:4 287
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This may indicate a selective loss of immunity against 
CMV not reflected by total CD4+ T-lymphocyte count, or 
an improvement in laboratory values before the restoration 
of protective immunity. Up to 69% of newly diagnosed 
cases are due to HAART failure, as measured by either 
persistently low CD4+ T-lymphocyte counts or high HIV 
RNA blood levels.17 Each of these factors independently 
predicts CMV reactivation. HAART failure patients more 
frequently present with asymptomatic, bilateral retinitis, 
better visual acuity, less zone 1 disease, and lesser lesion 
opacification. Since lesion opacification is believed to cor-
relate with viral activity, these patients have lower levels 
of viral replication.18 Milder disease also correlates with 
better visual acuity and fewer symptoms. Since many 
patients have asymptomatic disease, physicians should 
consider regular ophthalmic screening examinations of 
at-risk patients.
Although the diagnosis of CMV retinitis indicates that 
these patients have HAART failure, the milder ocular disease 
suggests that HAART has a beneficial effect on modulating 
disease severity and vision loss. HAART-treated patients 
have a lower incidence of retinal detachment,19 disease pro-
gression and second eye involvement.20 Despite this, HAART 
patients with CMV retinitis have an increased mortality rate, 
especially those with lower CD4+ T-lymphocyte counts.21
Intravenous therapy
Ganciclovir
Ganciclovir (Cytovene®, Roche Pharmaceuticals, Nutley, 
New Jersey, approved in 1989), the first anti-CMV drug, 
became available on a compassionate use basis in 1984. It is 
a synthetic acyclic nucleoside analog of 2′-deoxyguanosine. 
Following uptake by CMV-infected human cells, ganciclovir 
is monophosphorylated by the enzyme UL97 (the rate-
limiting step) and then triphosphorylated to its active form 
by activated kinases of the host cell. The triphosphate 
form interrupts viral DNA synthesis by competing with 
  deoxyguanosine triphosphate.
To achieve high tissue concentrations during induction, 
ganciclovir is administered twice daily at a dose of 5 mg/kg. 
Since maintenance therapy is anticipated to continue for 
weeks to months in most patients, a peripherally-inserted 
  central catheter (PIC) line is usually placed to allow 
  atraumatic, repeated intravenous access. Catheter-related 
bacterial or fungal sepsis (occurring in 12% of patients) 
remains an important complication.22
Ganciclovir excretion occurs by glomerular filtration 
and active tubular excretion via the kidneys23 and is directly 
related to creatinine clearance.24,25 Patients with mild (CLCR  
70 mL/min) to severe (CLCR  10 mL/min) renal impairment 
require lower ganciclovir doses because the areas under the 
Figure 2 retinitis is progressing from top to bottom: solid line points to area of necrotic retina following retinitis; dashed line points to area of active retinitis; dotted line 
points to area of normal retina.Clinical Ophthalmology 2010:4 288
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curve are increased by 1.8- to 15-fold. Dose adjustments 
appropriate to renal function are given in Table 1.
Ganciclovir causes hematologic abnormalities (neutrope-
nia, anemia, and thrombocytopenia) and probable long term 
reproductive toxicity. Women of reproductive age receiving 
ganciclovir need to be counseled about birth control. Patients 
with low neutrophil counts must discontinue ganciclovir or 
augment neutrophil synthesis with colony stimulating fac-
tors such as filgrastim (Neupogen®). Weekly subcutaneous 
injections usually raise neutrophil counts to acceptable levels 
(1000 cells/mL). Since both ganciclovir and zidovudine are 
similarly capable of causing leukopenia, patients receiving 
both drugs frequently require reduced doses.
Viral resistance to ganciclovir occurs most commonly due 
to mutations in the viral protein kinase UL97 gene, which 
is responsible for monophosphorylation of ganciclovir. The 
incidence of viral resistance increases with the duration of 
therapy from 2.2% at three months to 15.3% at 18 months.26 
Not surprisingly, viral resistance is associated with larger 
areas of retinitis and increased loss of vision.27
Foscarnet
Foscarnet (Foscavir®, AstraZeneca LP, Wilmington, Delaware, 
approved in 1991) is a pyrophosphate analog. It interferes with 
the binding of the diphosphate to the viral DNA polymerase of 
Herpes simplex, Varicella zoster, cytomegalovirus, and HIV.28
Daily induction dosing of foscarnet consists of 
180 mg/kg (usually given as 90 mg/kg twice daily) followed 
by maintenance therapy of 90 mg/kg once daily. Similar to 
ganciclovir, foscavir treatment usually lasts weeks to months, 
thereby requiring a PIC line.
Foscarnet is highly nephrotoxic and must be administered 
carefully to patients with renal disease. Patients require 
adequate hydration and frequent monitoring of creatinine 
levels. Viral resistance has been mapped to point mutations 
in the pol gene UL54. Cross-resistance between ganciclovir 
and foscarnet has been observed in numerous viral isolates 
with both phenotypic and genotypic resistance.28 Foscarnet 
is generally considered a second line therapy that is often 
administered to patients with ganciclovir-resistant viral 
strains or dose-limiting neutropenia.29
Cidofovir
Cidofovir (Vistide®, Gilead Sciences, Inc., Foster City, Califor-
nia, approved in 1996) is an acyclic nucleoside phosphonate. 
Following intracellular phosphorylation to the diphosphate 
form by host kinases, cidofovir targets the viral DNA poly-
merase by acting as a chain terminator. After incorporation at 
the 3′-end of the viral DNA chain, it terminates CMV DNA 
synthesis. Cidofovir is a broad spectrum antiviral agent with 
activity against CMV, acyclovir-resistant HSV infections, 
genital warts, laryngeal and cutaneous papillomatous lesions, 
molluscum contagiosum lesions, adenovirus infections, and 
progressive multifocal leukoencephalopathy (PML).30
The active form of cidofovir exhibits remarkable 
  intracellular stability (half-life  24 hours) thus allowing for 
infrequent dosing. Induction dosing consists of 5 mg/kg once 
weekly for two weeks, followed by 5 mg/kg every other week 
during maintenance. Mutations of the viral DNA polymerase 
UL54 gene result in viral resistance to cidofovir as well as 
foscarnet and ganciclovir.
Severe renal toxicity is the major limitation to long-term 
cidofovir therapy. Patients must be adequately hydrated and 
pretreated with oral probenicid to protect against kidney 
  failure. Due to the risk of renal toxicity and ocular hypotony, 
cidofovir is generally considered a second line therapy. 
Because of its association with immune recovery uveitis, cido-
fovir should not be used if immune recovery is expected.
Oral therapy
Ganciclovir
Oral ganciclovir was introduced in 1994 in an attempt to 
lower costs, eliminate the inconvenience of daily intravenous 
Table 1 recommended induction and maintenance dosing of iv ganciclovir adjusted for renal function63
Creatinine clearance 
(mL/min)
Ganciclovir-IV induction 
dose (mg/kg)
Dosing interval (hours) Ganciclovlr-IV maintenance 
dose (mg/kg)
Dosing interval  
(hours)
70 5.0 12 5.0 24
50–69 2.5 12 2.5 24
25–49 2.5 24 1.25 24
10–24 1.25 24 0.625 24
10 1.25 3 times per week,  
following hemodialysis
0.625 3 times per week, following 
hemodialysisClinical Ophthalmology 2010:4 289
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drug injections, reduce the risk of catheter-related sepsis, 
and improve patient quality of life.31 Maximum oral doses 
were 3 gm per day (12 capsules taken on a three times 
daily schedule), but since the bioavailability was only 6% 
to 9%, patients could not achieve plasma concentrations 
sufficient for induction therapy.22 The primary indica-
tion for oral ganciclovir was prevention of contralateral 
retinitis and non-ocular CMV disease in patients receiving 
intraocular therapy.32 When oral valganciclovir with its 
high bioavailability and convenient once-daily dosing was 
introduced, production and distribution of oral ganciclovir 
was discontinued.
valganciclovir
Valganciclovir (Valcyte®, Roche Pharmaceuticals, approved in 
2000) is an orally administered monovalyl ester prodrug of gan-
ciclovir. After absorption from the gut, valganciclovir undergoes 
rapid hydrolysis to ganciclovir in both the intestinal mucosa and 
liver. Ingesting valganciclovir with a high fat meal increases the 
area under the plasma concentration-time curve by 24% to 30%, 
without prolonging the time to peak concentration.33
Because of its high bioavailability (60%) valganciclovir 
can be used for both induction and maintenance therapy.34 
Induction therapy, typically 900 mg once daily for 2–3 weeks, 
results in serum ganciclovir levels 1.7 times those achievable 
with oral ganciclovir and comparable with those achieved 
with intravenous ganciclovir. Maintenance therapy is usually 
450 mg once daily. As with intravenous ganciclovir, dosing 
of valganciclovir should be decreased in patients with renal 
dysfunction (Table 2).
Oral valganciclovir is well tolerated, with the most com-
mon side effects being hematologic (neutropenia [16%], 
anemia [11%]), and gastrointestinal (diarrhea [13%], nausea 
[8%], and vomiting [4%]).22 Drug interaction studies with 
valganciclovir have not been performed, but since it under-
goes rapid conversion to ganciclovir, interactions are likely to 
be the same as with ganciclovir. Oral valganciclovir therapy 
is associated with a low incidence of viral resistance.
Intravitreal therapy
During the 1980s and 1990s intravitreal drug injections 
were given to patients who were intolerant of or refused 
systemic therapy. Several non-controlled studies show that 
most patients respond to induction therapy with each of the 
available drugs. Anti-CMV drugs can be injected in the office 
with topical anesthesia and sterile preparation of the eye with 
povidone-iodine solution (Figure 3). Although post-injection 
antibiotic drops have not been proven to lessen the incidence 
of endophthalmitis, most surgeons recommend broad spec-
trum treatment for 3–4 days.
Intravitreal injections of ganciclovir result in high retinal 
tissue concentrations without systemic bone marrow suppres-
sion. Since ganciclovir is supplied as a highly soluble powder, 
a wide range of concentrations can be formulated. Repeated 
doses ranging from 200 µg/0.1 mL to 2000 µg/0.1 mL have 
been injected into eyes without observable retinal toxicity.35,36 
An accidently administered dose of 6 mg caused no harm, but 
40 mg resulted in retinal damage. Twice-weekly injections 
are given during the induction phase, followed by weekly 
injections during maintenance. Time to disease progression 
has been estimated to be eight weeks.37
Few noncontrolled studies of intravitreal foscarnet injec-
tions have been published.38–40 In the largest series, 11 patients 
experienced successful induction therapy (six injections of 
2400 µg given at 72-hour intervals) followed by weekly mainte-
nance injections. Reactivation of the retinitis occurred in 33.3% 
of patients within 20 weeks. Since foscarnet is distributed as a 
solution, higher drug concentrations cannot be made.
Cidofovir has a narrow therapeutic index for intravitreal 
injections, unlike ganciclovir which has a wide therapeutic 
index. Despite the manufacturer’s warning against intravitreal 
administration,41 cidofovir has been injected into a small 
number of eyes. Cidofovir injections (20 µg every 5–6 weeks) 
have been effective as induction therapy. With a mean fol-
lowup of 15 weeks, 7.5% of patients (all previously treated 
with intravenous ganciclovir, foscarnet or both) experienced 
progression of their retinitis. Post-injection uveitis occurs 
frequently (17%; 41% in those not receiving prophylaxis 
with oral probenecid). Many patients experience a transient 
reduction in intraocular pressure and 3% develop irreversible 
hypotony with severe vision loss.42 A double-masked, ran-
domized trial of three cidofovir doses (5 µg, 10 µg, and 15 µg) 
was prematurely terminated due to high incidences of iritis 
(87%) and hypotony (16%), and low efficacy.43 Intravitreal 
administration of cidofovir is no longer recommended.
Fomiversin (Vitravene®, Novartis Ophthalmics AG, 
Bulach, Switzerland, and Isis Pharmaceuticals, Inc, 
Table 2 recommended induction and maintenance dosing of oral 
valganciclovir adjusted for renal function49
Creatinine 
clearance (mL/min)
Induction 
dosage (mg)
Maintenance 
dosage (mg)
60 900 BiD 900 QD
40–59 450 BiD 450 QD
25–39 450 QD 450 every other day
10–24 450 every other day 450 twice weekly
10 Not recommended Not recommendedClinical Ophthalmology 2010:4 290
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Carlsbad, California, approved in 1998) is an antisense 
  oligodeoxynucleotide that hybridizes with and blocks 
  expression of CMV mRNA. Two intravitreal injections every 
other week were followed by monthly maintenance injections. 
The major complication was mild uveitis which was treated 
with topical corticosteroids. Production and distribution of 
fomivirsen has been discontinued.
The efficacy of intravitreal injections must be weighed 
against several inherent disadvantages. Weekly injections 
during the maintenance phase may be inconvenient for both 
the patient and physician. Although generally safe, intravitreal 
injections may be complicated by vitreous hemorrhages 
(3%), retinal detachments (8%), and endophthalmitis. 
Since CMV retinitis arises from active blood-borne disease, 
patients receiving intravitreal injections remain at risk for 
  contralateral eye disease (11%–30%), non-ocular end-organ 
infections (16%), and increased mortality.44–47 Most experts 
recommend that patients treated with intravitreal injections 
also receive systemic therapy with oral valganciclovir (most 
frequently) or one of the intravenous drugs.
Ganciclovir implant
The efficacy and safety of intraocular therapy, combined with 
the absence of systemic toxicity, spurred the development 
of the sustained-release ganciclovir implant (Vitrasert®, Bausch 
and Lomb, Inc., San Dimas, California, approved in 1996). 
This polyvinyl alcohol/ethylene vinyl acetate device releases 
ganciclovir from a 4.5 mg capsule at a rate of 1 µg/hr for up to 
nine months. In a randomized study, the implant extended the 
mean time to retinitis progression well beyond that achieved 
with intravenous therapy (221 days vs 76 days).48
The reservoir is surgically implanted through a 
pars plana incision and secured with a non-absorbable 
  transscleral suture (Figure 4). A transient decrease in 
visual acuity occurs during the first two weeks following 
implantation. The risk of retinal detachment rises in the 
early post-operative period but decreases in the long term 
due to superior control of the retinitis. Since retinitis usu-
ally recurs when the ganciclovir implant empties, many 
surgeons either replace the implant after 32 weeks or, to 
avoid reopening the previous incisions, place an additional 
implant through a different pars plana site.
Treatment strategies
Improved patient survival with HAART has shifted the 
focus of anti-CMV treatment from short-term suppression 
of disease to long-term maintenance of vision. This means 
combining immune system reconstitution with effective 
short- or long-term anti-CMV therapy.
For patients not taking antiretroviral medications, one 
must first consider starting HAART; for HAART-failure 
patients, changing medications should be considered. Some 
infectious disease specialists will consider delaying HAART 
in patients with opportunistic infections to minimize the risk 
of immune recovery syndromes (immune recovery uveitis in 
patients with CMV retinitis).
Figure 3 intravitreal injection of ganciclovir through the pars plana.Clinical Ophthalmology 2010:4 291
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Treatment of CMV retinitis should be individualized, 
taking into account the size and location of the retinitis, the 
patient’s experience with HAART, and the risk of treatment-
related complications. The location of infected retina deter-
mines the risk for vision loss; posterior retinitis threatens 
the macula and optic nerve; and anterior retinitis increases 
the risk of retinal detachment. The ocular fundus is divided 
into three zones; zone 1 encloses the area within 1500 µm of 
the nerve or 3000 µm of the fovea, zone 2 includes the area 
outside of zone 1 but posterior to the equator (as defined by 
the vortex veins), and zone 3 includes the peripheral retina 
between the equator and the ora serrata (Figure 5).8
Since CMV retinitis patients have a high risk of death 
that can be decreased by anti-CMV therapy, all patients, if 
possible, should receive systemic medication as part of the 
treatment regimen.21,46
To suppress viral replication rapidly and minimize 
  systemic complications (usually neutropenia and renal 
  toxicity), early protocols developed the two-phase treatment 
strategy. A two- to three-week period of frequent, high-
dose drug administration to stop viral replication (induction 
phase) was followed by a continuous period of lower-dose 
therapy to suppress viral activity for as long as possible 
(maintenance phase). Induction therapy for CMV retinitis 
is usually with one of four available drugs, ie, ganciclovir, 
foscavir, cidofovir (all intravenous), oral valganciclovir, or 
surgical placement of the intravitreal ganciclovir implant. 
The choice of anti-CMV therapy is usually based on efficacy 
and tolerability profiles, pharmacologic considerations, and 
quality of life issues (Table 3).49 Comparison studies (intra-
venous ganciclovir with oral ganciclovir or intravenous 
foscarnet25,50,51 or cidofovir52) have failed to show significant 
differences between drug choices. Throughout the course of 
treatment, patients and physicians must remember that these 
drugs suppress CMV replication but do not eliminate the 
virus from the eye. Unless the patient experiences adequate 
reconstitution of the immune system, retinitis treatment must 
be continued indefinitely.
Episodes of relapse (also termed progression), defined as 
centrifugal advancement of the lesion borders, were expected 
with intravenous therapy. Early relapses were attributed to 
inadequate ocular drug concentrations,53,54 whereas later 
relapses were increasingly associated with acquired drug 
resistance.55–57 Unfortunately, the pace of relapses appeared 
to accelerate with the duration of treatment. Relapses were 
retreated with induction phase dosing, and this cycle was 
repeated until the patient’s death. Except for therapy with 
the intravitreal ganciclovir implant, this strategy continues 
to be used.
For most patients, valganciclovir is the drug of choice, 
due to its lower cost and lower complication rate, as well as 
convenient oral administration. Induction therapy (900 mg 
Figure 4 Sustained-release ganciclovir implant sutured to the pars plana as seen through the pupil.Clinical Ophthalmology 2010:4 292
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once daily) has been shown to be as effective as intravenous 
ganciclovir (5 mg/kg twice daily).58 This regimen arrests 
CMV progression in 90% of eyes and achieves a satisfac-
tory clinical response in 72% of patients. Median time to 
progression is 160 days, compared with 125 days in patients 
receiving intravenous ganciclovir induction therapy followed 
by oral ganciclovir maintenance. Among the 10% of patients 
who did not respond favorably to induction, 71% progressed 
within the first two weeks. The relative risk of progression 
in the valganciclovir group (compared with the ganciclovir 
group) was 0.9 (95% CI: 0.58, 1.38). The incidence of retinal 
detachment was 19% in each group. Systemic CMV suppres-
sion, as measured by serum, blood, and urine cultures, and 
PCR assay, occurred in both groups.
Each available anti-CMV drug regimen has associated 
disadvantages. Intravenous ganciclovir and foscarnet require 
indwelling catheters which increase cost, create inconve-
nience, and expose patients to the risk of secondary sepsis. 
Daily ganciclovir infusions last one hour, but each of three 
daily foscarnet infusions lasts two hours. The infrequent 
dosing of cidofovir does not require an indwelling catheter; 
however, the high risk of dose-related, potentially irreversible 
Figure 5 Diagram of the retina shows the three anatomic zones used for classification of CMV retinitis.Clinical Ophthalmology 2010:4 293
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nephrotoxicity (up to 50%) requires pre-treatment with 
probenicid and adequate hydration.59 Nephrotoxicity and 
uveitis (seen in 10% of patients receiving the intravenous 
formulation) limit the use of cidofovir.60
The ganciclovir implant more effectively delays retinitis 
progression, but surgical implantation carries significant 
operative cost and comorbidities, such as endophthalmitis 
and retinal detachment.61 For HAART-naïve patients who 
may be expected to recover immunity against CMV, the eight 
months of continuous drug release may not be necessary. 
However, for patients with sight-threatening zone 1 retinitis, 
where rapid disease inactivation is critical to maintain vision, 
the implant, in combination with oral therapy, may be the 
best initial therapeutic choice (Table 4).32 While surgery 
is being planned, intravitreal injections of ganciclovir can 
quickly establish high intraocular antiviral levels to prevent 
disease progression.62 Since immune recovery is the most 
important factor for long-term CMV control, patients whose 
HAART therapy cannot be improved should be considered 
for implant surgery. Unless patients with the ganciclovir 
implant also receive systemic anti-CMV therapy, they are at 
high risk of developing both contralateral retinitis and extra-
ocular CMV disease. Compared with intravenous therapy, 
oral valganciclovir equally prevents and treats non-ocular 
CMV disease. Valganciclovir has been shown to prevent the 
development of systemic CMV disease in 83% of patients 
and contralateral retinitis in 94% of cases.22
The introduction of valganciclovir rapidly changed 
  preferred treatment patterns. A retrospective analysis of 
insured patients in the US evaluated anti-CMV treatment 
from 1997 to 2002. The use of intraocular therapy changed 
minimally (13.3% to 15.8%) whereas the use of oral drugs 
increased from 9.6% to 43.4%, at the expense of intravenous 
therapy, which decreased from 77.1% to 40.8%. This may 
be due in part to the lower cost of oral valganciclovir ($69 
US/day vs $163 US/day for the intravenous preparation).63
The rate of CMV reactivation has fallen from 3.0 
cases/PY (pre-HAART) to 0.1 case/PY (post-HAART), with 
most of the improvement attributed to immune recovery.19 
  Reactivation of CMV retinitis can usually be successfully 
retreated with induction therapy and anecdotal reports 
  suggest that repeat induction therapy in HAART-treated 
patients may require less aggressive therapy than in the   
pre-HAART era.64 Recurrent disease always raises the con-
cern of drug resistance, but the prevalence of drug-resistant 
CMV has fallen (from 28% to 9%) since the introduction 
of HAART.65 Patients with drug-resistant infections can be 
difficult to treat and may require therapy with foscarnet or 
cidofovir.
Table 3 Summary of dosing, adverse events, advantages and disadvantages of the available four systemic anti-CMv drugs49
Feature Ganciclovir Foscarnet Cidofovir Valganciclovir
induction regimen IV: 5 mg/kg BiD for  
2–3 weeks Implant:  
4.5 mg q5–8 months
IV: 60 mg/kg TiD for  
2–3 weeks
IV: 5 mg/kg qwk for 2 wk PO: 900 mg BiD  
for 3 wk
Maintenance regimen IV: 5 mg/kg QD  
Implant: 4.5 mg q5–8 months
IV: 30–40 mg/kg TiD IV: 5 mg/kg q2 wk PO: 900 mg QD
Main adverse events IV: Bone marrow 
suppression  
Implant: post-operative ocular 
complications
Nephrotoxicity Nephrotoxicity and uveitis Bone marrow 
  suppression
Advantages IV: systemic therapy Implant: 
longest time to retinitis 
progression in treated eye
Systemic therapy; anti-Hiv 
activity
Systemic therapy; least 
expensive iv regimen; 
infrequent dosing; no 
indwelling venous catheter
Systemic therapy; 
  convenient QD dosing; 
low pill burden; no iv 
catheter required
Disadvantages IV: hematologic toxicity 
Implant: requires 
surgery; local effects only; 
post-operative ocular 
  complications; expensive
Nephrotoxicity; prolonged 
daily infusions with 
infusion pump
Nephrotoxicity; requires 
probenicid and hydration
Hematologic toxicity
Table 4 Suggested treatment strategy for patients with newly 
diagnosed CMv retinitis62
CMV retinitis 
location
HAART 
experienced
HAART naïve
Zone 1 Ganciclovir implant +  
valganciclovir
Ganciclovir implant + 
valganciclovir
Zones 2 and 3 valganciclovir ± ganciclovir 
implant
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Reconstitution of the immune system following initiation 
of HAART can be sufficient to suppress CMV retinitis in 
some patients. More commonly, immune recovery allows for 
the discontinuation of anti-CMV therapy without rebound 
CMV reactivation in many patients. Long term studies show 
that patients with non-sight-threatening, quiescent retinitis for 
six months, and reconstitution of the immune system, may 
be considered for discontinuation of anti-CMV medications. 
The decision to stop CMV therapy depends upon many 
factors, including rising CD4+ T-lymphocyte counts, 
falling systemic HIV loads (preferably to undetectable), 
duration of HAART (at least three months), and inactiv-
ity of CMV lesions. The US Centers for Disease Control 
(CDC) recommends that the CD4+ T-lymphocyte be at least 
100–150 cells/µL for 3–6 months before CMV therapy is 
discontinued.66 However, most authors require more robust 
evidence of immune reconstitution (ie, CD4+ T-lymphocyte 
counts 200 cells/µL; 100-fold drop in HIV blood levels) 
before discontinuing therapy.67,68 Contradicting studies have 
reported successful discontinuation of therapy despite HIV 
blood levels exceeding 30,000 copies/mL.64
Once anti-CMV therapy has been discontinued, patients 
need close monitoring of their ophthalmologic status with 
attention to falling CD4+ T-lymphocyte counts, and rising 
HIV blood loads. The risk of CMV reactivation is estimated 
to be 0.02 events/PY.64,68 Correlation exists between rising 
systemic CMV Ag titers and DNA levels, and reactivation 
of retinitis, but the predictive value of these tests remains 
insufficient to warrant routine screening.69 Serial oph-
thalmologic examinations at three-monthly intervals are 
frequently recommended, although supportive data for this 
practice does not exist. At-risk patients should be counseled 
to test themselves frequently for changes in visual acuity 
and peripheral fields; changes should be reported to their 
  ophthalmologist immediately. Stopping anti-CMV therapy 
incurs reduced costs, decreased pill load, fewer complica-
tions, and better compliance with antiretroviral therapy.
Immune recovery many not occur for up to three months 
after institution of HAART, making patients susceptible 
to opportunistic infections (including CMV retinitis) dur-
ing this period. An estimated 8% to 15% of CMV retinitis 
patients contracted their disease after apparently successful 
HAART-induced immune reconstitution.70 Generalized 
expansion of CD4+ T-lymphocyte populations, but not the 
clones with specific anti-CMV memory, may allow retinitis 
to develop.
Pharmacologic prophylaxis against CMV disease in   
at-risk AIDS patients is clinically neither beneficial71 nor cost 
effective.72 A small study failed to prevent end-organ dis-
ease when anti-CMV therapy was given to HAART-treated 
patients with viremia (Wohl unpublished data 2006).
Unseen in the pre-HAART era, the immune-reconstitution 
inflammatory syndromes frequently complicate HAART 
therapy. Although these disorders have been given several 
names, immune reconstitution inflammatory syndrome 
(IRIS) has become the most widely accepted general term,73 
with immune recovery uveitis (IRU) given to ocular inflam-
mation. IRU occurs when the recovered immune system 
recognizes and then reacts to a large intraretinal CMV 
antigen load.
IRIS occurs in 15% to 25% of HIV-positive patients 
receiving HAART, with the highest incidence between eight 
and 16 weeks after initiation of treatment.74 Patients with low 
CD4+ T-lymphocyte counts (fewer than 50 cells/µL),75 large 
areas of CMV retinitis (25% to 30% of the retina),16 and a 
history of cidofovir use74 have the greatest risk of IRU. For 
patients who have had CMV retinitis, IRU occurs in 9.6% of 
those with immune recovery.16 The rate of visual impairment 
in HAART-treated patients is 0.1 cases/eye year (EY) and the 
rate of blindness is 0.06 cases/EY. The rate of visual impair-
ment in IRU patients is 0.17 cases/EY.76 Although unusual, 
patients with partial immune reconstitution may develop IRU 
in the presence of persistent CMV retinitis.70
Immune recovery uveitis usually coincides with a rapid 
reconstitution of the immune system, as measured by an 
increase in the CD4+ T-lymphocyte count. A small percent-
age of patients, however, develop IRU without a CD4+ T-
lymphocyte increase, suggesting that improved immunity 
against CMV may occur by some as yet unrecognized 
mechanism.76,77 Affected patients have undetectable CMV 
DNA in blood and vitreous specimens. The clinical spectrum 
of IRU ranges from asymptomatic vitritis, through mild tran-
sient vitritis, to a persistent uveitis with floaters, decreased 
vision, cystoid macular edema (12.3 × increased risk) and 
epiretinal membrane (3.7 × increased risk) formation.78,79 
Uveitis is believed to be directed toward residual CMV DNA 
at the edge of previous retinitis.80 Infrequent complications 
include neovascularization, disc edema, proliferative vit-
reoretinopathy, cataract and posterior synechiae.76 Although 
some patients experience severe vision loss (20/200 or 
worse), most patients have visual acuities between 20/50 
and 20/200.
HAART-treated patients diagnosed with IRU need 
to have other inflammatory conditions (syphilis, herpetic   
retinitis, drug toxicity) excluded. PCR testing of intraocular 
fluids may help rule out infectious etiologies.81Clinical Ophthalmology 2010:4 295
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In attempting to avoid IRU, some investigators 
  recommend delaying HAART therapy until CMV retini-
tis is controlled. A small study reported a decreased rate 
of IRU when HAART was delayed until after induction 
therapy for CMV. This delay strategy carries significant 
risk given that infected patients have a high risk of death 
during the period immediately following diagnosis of 
CMV retinitis.82
Treatment of IRU depends upon the severity of the 
  inflammation and the responsiveness of the complications. 
Mild inflammation with macular edema can some-
times be treated effectively with topical and periocular 
  corticosteroids83,84 but other eyes are refractory to treatment.85 
Intravitreal corticosteroids have successfully treated eyes 
refractory to less aggressive treatment but, in addition to the 
usual complications of cataracts and glaucoma, reactivation 
of retinitis may occur.85,86 The sustained-release intravitreal 
fluocinolone implant has successfully resolved inflammation 
and edema but has also caused reactivation of retinitis.87,88 To 
prevent CMV reactivation following corticosteroid treatment, 
some authors recommend restarting anti-CMV therapy.89 
Surgery for cystoid macular edema, cataract, vitritis, and 
epiretinal membranes has yielded mixed results.87
Retinal detachments affected up to 40% of CMV-infected 
eyes (0.5 cases/PY) in the pre-HAART era. Post-HAART, 
the overall rate of detachment has fallen to 0.06 cases/PY, 
but remains high in patients with CD4+ T-lymphocyte 
counts less than 50 cells/µL.19 Since many of these eyes had 
large areas of necrotic retina with persistent vitreoretinal 
traction, standard reattachment techniques (scleral buckle, 
vitrectomy with fluid/air exchange) were frequently unsuc-
cessful. Vitrectomy with silicone oil tamponade quickly 
became the surgical procedure of choice. Despite successful 
reattachment, patients frequently lost vision due to cataract, 
aniseikonia, and for unknown reasons. Although silicone oil 
removal can improve visual acuity, it carries a 53% risk of 
retinal redetachment.
Now that patients are living much longer, and retinal 
detachment repair with silicone oil carries a poor visual 
prognosis, surgeons should consider attempting initial repair 
with air tamponade with or without scleral buckle.90 Patients 
for whom this approach is most appropriate may be those 
with peripheral disease for which posterior delimiting laser 
photocoagulation can be safely placed.91
CMV in developing countries
The previous sections of this review discuss the optimal 
treatment of CMV retinitis while assuming that sufficient 
resources (HAART, anti-CMV drugs, health personnel, 
access to care) are available to affected patients. Although 
developed countries usually provide these resources, under-
developed countries frequently lack one or more components. 
Consequently, patients may receive “substandard” care, 
with a higher likelihood of vision loss and decreased life 
expectancy.
At present 90% of HIV-infected people live in the 
developing countries of sub-Saharan Africa, the Indian 
subcontinent, Latin America, and Southeast Asia. Significant 
regional variability exists in the prevalence of opportunistic 
infections, with high rates of tuberculosis, cryptococcus and 
pneumocystis pneumonia.
An estimated 5% to 25% of AIDS patients in developing 
countries will develop blindness.92 The incidence of CMV 
retinitis in India varies from 2% in HAART-treated patients 
(with another 6% of patients developing IRU)93 to 20% (35% 
of which were active infection; 65% were healed lesions), 
with the majority of these receiving HAART.94 Biswas et al 
reported that 17% of HAART-naïve patients had CMV reti-
nitis95 and eight years later the same authors reported that 
the incidence had fallen to 5.7%.96 Up to 25% of patients 
with a history of CMV retinitis develop IRU.94
The incidence of CMV retinitis in sub-Saharan Africa 
varies from 0% to 19.6%.97–101 In Malawi the prevalence 
of anterior segment AIDS-related eye disease was 13%, 
whereas retinitis was seen in only 1% of patients.102 None of 
56 patients in a Gambian study had retinitis.103 CMV retinitis 
developed in 0.2% of HAART-naïve patients in Ethiopia99 
but 19.8% of HAART-treated patients in Thailand.101 The 
low prevalence of HIV-related eye disease in Africa may be 
due to patients dying before developing ocular opportunistic 
infections.92,104 The low incidences observed in Africa differ 
from those reported in India, suggesting that the diagno-
sis of retinitis may depend more upon access to medical 
care than on racial or geographic differences.105 Regional 
variations in the prevalence of opportunistic organisms 
and government-sponsored HAART distribution programs 
may also account for the lower incidence of CMV retinitis 
in some areas.
The experience at one Indian referral center illustrates 
the consequences of health funding shortfalls facing 
developing countries. Ten of 23 newly diagnosed CMV 
retinitis patients received two weeks of induction therapy 
(intravenous ganciclovir) followed by one week of mainte-
nance. Limited resources prevented the continued adminis-
tration of systemic maintenance therapy, but three patients 
received intravitreal ganciclovir injections.95Clinical Ophthalmology 2010:4 296
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Indian cost and income data from 2000 illustrates the 
financial challenges in treating CMV retinitis patients: 
intravenous ganciclovir therapy costs $714/month, anti-
HIV therapy costs $547/month, with the average per capita 
income being only $380/month. Working within these finan-
cial constraints, intravitreal ganciclovir injections emerge 
as the most cost-effective, available method of controlling 
CMV retinitis. Intravitreal ganciclovir injections have 
been successfully used at selected centers in South Africa, 
Botswana,97 and Thailand,101 and intravitreal foscarnet has 
been used for both induction and maintenance therapy.106 
A Thai economic model suggested that CMV retinitis treat-
ment with intravenous ganciclovir or oral valganciclovir 
would be cost-effective, whereas intravitreal ganciclovir 
injections would be cost-effective for patients not receiving 
HAART.107 Although injections fail to prevent non-ocular 
CMV infection and contralateral CMV retinitis, and may not 
extend life expectancy, they allow patients the opportunity 
to maintain useful vision.
Effective intravitreal therapy regimens require adequately 
trained ophthalmic professionals to perform early screening 
eye examinations, regular followup examinations and intra-
vitreal injections. Unfortunately, many developing countries 
are deficient in trained ophthalmic personnel. Perhaps the 
challenges involved in treating CMV retinitis were best sum-
marized by Shah: “The availability and cost of drugs such as 
ganciclovir and followup for ocular diseases such as CMV 
retinitis limit the visual outcome in these patients.”
Many patients fail to return for followup examina-
tions after being diagnosed with CMV retinitis.96 Although 
some authors recommend ophthalmic screenings of at-risk 
patients,108 limited resources make such programs difficult 
to implement. HIV-infected patients in India do not receive 
routine ophthalmologic examinations and are seen only if 
they become symptomatic.96 The incidence of CMV retinitis, 
particularly in patients with asymptomatic zone 3 disease, may 
be underestimated because of inadequate ophthalmic screen-
ing programs. Additionally, inadequate followup of patients 
with diagnosed CMV retinitis patients may doom them to 
blindness because of unchecked disease progression.
HAART generally decreases the incidence of CMV 
retinitis and, through reconstitution of the immune system, 
establishes long term remission. In developing countries 
this requires government and non-government agencies to 
provide medical care and anti-HIV medications at afford-
able prices.109 The governments of India and Thailand now 
provide anti-HIV medications free of charge to all infected 
patients.101,110 Increasing availability of HAART in countries 
such as India may change the incidence of CMV retinitis due 
to several factors, including longer survival, improved immu-
nologic status, and increased incidence of immune recovery 
uveitis.93 However, despite the availability of HAART, AIDS 
patients in low-income countries have higher mortality rates 
than those in high-income countries.111
Future
Currently available anti-CMV drugs have unfavorable 
  toxicity profiles, and foscarnet and cidofovir have insufficient 
bioavailability to be administered orally. A need remains for 
an effective oral agent with minimal toxicity.
The CMV epidemic associated with AIDS drove the 
development of anti-CMV medications during the 1980s 
and 1990s but the introduction of HAART, with the resultant 
dramatic decrease in CMV retinitis, served to slow drug 
development. However, during the same period, advances in 
organ procurement, surgical instrumentation and techniques, 
and anti-rejection drugs have enabled organ transplant 
programs to flourish. Organ recipients are at high risk of 
non-ocular CMV, which is now called the “troll” of organ 
transplant patients. Their need for chronic CMV suppression 
has served to re-stimulate drug development. Future drug 
development may, therefore, depend upon success in organ 
recipient trials.
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